GLPwatch
Papers (9189)
Page 65 of 154, ranked by citation count.
- Improvement of cognitive function, glucose and lipid homeostasis and serum osteocalcin levels by liraglutide in diabetic rats.
- Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review.
- Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.
- Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes.
- Effects of leptin replacement alone and with exendin-4 on food intake and weight regain in weight-reduced diet-induced obese rats.
- Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.
- Neonatal exendin-4 reduces growth, fat deposition and glucose tolerance during treatment in the intrauterine growth-restricted lamb.
- Orally administered intelligent self-ablating nanoparticles: a new approach to improve drug cellular uptake and intestinal absorption.
- Effect of liraglutide on dietary lipid-induced insulin resistance in humans.
- Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors.
- A Review on the Efficacy and Safety of Oral Semaglutide.
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors among Obese/Overweight Individuals Treated with Antipsychotic Drug Classes: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease.
- Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice.
- Lixisenatide attenuates advanced glycation end products (AGEs)-induced degradation of extracellular matrix in human primary chondrocytes.
- Diabetes Treatment in the Elderly: Incorporating Geriatrics, Technology, and Functional Medicine.
- Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
- Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes.
- Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity.
- Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom.
- GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells.
- Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential.
- GLP-1R agonist promotes proliferation of neuroendocrine neoplasm cells expressing GLP-1 receptors.
- Clinical Trial Highlights - GLP-1 agonists.
- Is there an association between liraglutide use and female breast cancer in a real-world setting?
- Liraglutide in combination with acitretin for severe recalcitrant psoriasis.
- Liraglutide promotes the angiogenic ability of human umbilical vein endothelial cells through the JAK2/STAT3 signaling pathway.
- Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus.
- Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity.
- Exenatide Attenuates Non-Alcoholic Steatohepatitis by Inhibiting the Pyroptosis Signaling Pathway.
- Effects of Exenatide on Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes.
- The glucagon-like peptide-1 (GLP-1) analog exenatide ameliorates intrauterine adhesions in mice.
- Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study.
- Exendin-4 protects hindlimb ischemic injury by inducing angiogenesis.
- Correlated increase of omentin-1 and adiponectin by exenatide, avandamet and dietary change in diet-induced obese rats.
- Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?
- Micellar Nanomedicine of Novel Fatty Acid Modified Xenopus Glucagon-like Peptide-1: Improved Physicochemical Characteristics and Therapeutic Utilities for Type 2 Diabetes.
- Identification of glycosylated exendin-4 analogue with prolonged blood glucose-lowering activity through glycosylation scanning substitution.
- Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.
- STEP 1 for Effective Weight Control - Another First Step?
- Differential mobility spectrometry tandem mass spectrometry with multiple ion monitoring for the bioanalysis of liraglutide.
- Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models.
- GLP1 receptor agonism protects against acute olanzapine-induced hyperglycemia.
- Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.
- Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect.
- The GLP-1 receptor agonist exenatide reduces serum TSH by its effect on body weight in people with type 2 diabetes.
- Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials.
- The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m<sup>2</sup>.
- Therapeutic Effects of Liraglutide, Oxytocin and Granulocyte Colony-Stimulating Factor in Doxorubicin-Induced Cardiomyopathy Model: An Experimental Animal Study.
- Analysis of the interferences in quantitation of a site-specifically PEGylated exendin-4 analog by the Bradford method.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom.
- Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study.
- Target-mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus.
- Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management.
- Continuous subcutaneous insulin infusion combined with liraglutide reduced glycemic variability and oxidative stress in type 2 diabetes mellitus: a study based on the flash glucose monitoring system.
- Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes.
- Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
- Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
- Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease.
- Neural-Derived Extracellular Vesicles in Clinical Trials: Message in a Bottle.